F S&P 500
5,203.75 -9.00 (-0.17%) F Dow Jones
39,145.00 -50.00 (-0.13%) F Nasdaq
18,143.25 -43.25 (-0.24%) E-mini Russell 2000 Index Futur
2,058.20 -6.60 (-0.32%) Petróleo
79.37 +0.38 (+0.48%) Oro
2,322.10 -0.20 (-0.01%)
Nyxoah S.A. (NYXH)
Nyxoah S.A.
Rue Edouard Belin 12
Mont-Saint-Guibert 1435
Belgium
32 10 22 23 55
https://www.nyxoah.com
Sector(es): Healthcare
Industria: Medical Instruments & Supplies
Empleados a tiempo completo: 146
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Robert Taub MBA | Co-Founder & Chairman | 137.21k | N/D | 1947 |
| Mr. Olivier Taelman | CEO & Executive Director | 867.63k | N/D | 1972 |
| Mr. Loic Moreau | Chief Financial Officer | 503.84k | N/D | 1981 |
| Mr. Bruno Onkelinx | Chief Technology Officer | N/D | N/D | N/D |
| Mikaela Kirkwood | Corporate Communication & Investor Relations Manager | N/D | N/D | N/D |
| Ms. An Moonen | General Counsel | N/D | N/D | N/D |
| Mr. Remi Renard | Vice President of Market & Market Access | N/D | N/D | N/D |
| Ms. Inge Vanwittenbergh | Global Human Resource Director | N/D | N/D | N/D |
| Mr. David M. DeMartino | Chief Strategy Officer | N/D | N/D | N/D |
| Mr. Jeyakumar Subbaroyan | Chief Clinical Officer | N/D | N/D | N/D |
Descripción
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Gestión corporativa
La calificación ISS Governance QuickScore de Nyxoah S.A. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
